- Home
- ARR vs MNKD Comparison
ARR vs MNKD Comparison
Compare ARR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | MNKD |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | ARR | MNKD |
|---|---|---|
| Price | $17.63 | $5.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $18.17 | $10.08 |
| AVG Volume (30 Days) | ★ 3.3M | 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 16.29% | N/A |
| EPS Growth | N/A | ★ 350.00 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $285,504,000.00 |
| Revenue This Year | $296.22 | $21.29 |
| Revenue Next Year | $99.47 | $25.53 |
| P/E Ratio | ★ $27.18 | $77.64 |
| Revenue Growth | N/A | ★ 43.50 |
| 52 Week Low | $13.18 | $3.39 |
| 52 Week High | $19.31 | $6.51 |
Technical Indicators
Market Signals| Indicator | ARR | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 45.24 |
| Support Level | $17.03 | $5.54 |
| Resistance Level | $18.61 | $6.05 |
| Average True Range (ATR) | 0.45 | 0.26 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 37.22 | 14.20 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.